You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDigitoxin
Accession NumberDB01396
TypeSmall Molecule
GroupsApproved
DescriptionA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Structure
Thumb
Synonyms
Crystodigin (tn)
Digitoksin
Digitoxin
Digitoxinum
Digitoxoside
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Digitaline Welcker Tab 0.1mgTablet.1 mgOralWelcker Lyster Ltd., Division Of Technilab Inc.1951-12-312001-09-05Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CrystodiginNot Available
TardigalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIE90NZP2L9U
CAS number71-63-6
WeightAverage: 764.9391
Monoisotopic: 764.434692134
Chemical FormulaC41H64O13
InChI KeyWDJUZGPOPHTGOT-XUDUSOBPSA-N
InChI
InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[[email protected]](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](O)[[email protected]](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
Pharmacology
IndicationFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
Structured Indications Not Available
PharmacodynamicsDigitoxin is a cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current UK medical practice. While there have been several controlled trials which have shown digoxin to be effective in a proportion of patients treated for heart failure, there is not the same strong evidence base for digitoxin, although it is presumed to be similarly effective.
Mechanism of actionDigitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityDigitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDigitoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolDigitoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideDigitoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidDigitoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidDigitoxin may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineDigitoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineDigitoxin may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineDigitoxin may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneDigitoxin may decrease the cardiotoxic activities of Abiraterone.Approved
ABT-263Digitoxin may decrease the cardiotoxic activities of ABT-263.Investigational
AcebutololAcebutolol may increase the bradycardic activities of Digitoxin.Approved
AcetaminophenThe serum concentration of Digitoxin can be increased when it is combined with Acetaminophen.Approved
AclarubicinDigitoxin may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideDigitoxin may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibDigitoxin may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneDigitoxin may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptDigitoxin may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinDigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleDigitoxin may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinDigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Digitoxin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Digitoxin can be increased when it is combined with Alectinib.Approved
AlemtuzumabDigitoxin may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
AlfentanilThe serum concentration of Digitoxin can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinDigitoxin may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineDigitoxin may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
AlprenololAlprenolol may increase the bradycardic activities of Digitoxin.Approved, Withdrawn
AltretamineDigitoxin may decrease the cardiotoxic activities of Altretamine.Approved
AmantadineThe serum concentration of Digitoxin can be increased when it is combined with Amantadine.Approved
Amg 386Digitoxin may decrease the cardiotoxic activities of Amg 386.Investigational
AmikacinThe serum concentration of Digitoxin can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Amiloride.Approved
AminocamptothecinDigitoxin may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideDigitoxin may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Digitoxin can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidDigitoxin may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Digitoxin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Digitoxin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Digitoxin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Digitoxin can be increased when it is combined with Amodiaquine.Approved
AmonafideDigitoxin may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.Approved, Investigational
AmprenavirThe serum concentration of Digitoxin can be decreased when it is combined with Amprenavir.Approved
AmrubicinDigitoxin may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineDigitoxin may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideDigitoxin may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleDigitoxin may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveDigitoxin may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinDigitoxin may decrease the cardiotoxic activities of annamycin.Investigational
Aop200704Aop200704 may increase the bradycardic activities of Digitoxin.Investigational
AP 12009Digitoxin may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Digitoxin may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneDigitoxin may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Digitoxin can be decreased when it is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Digitoxin can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinThe serum concentration of Digitoxin can be decreased when it is combined with Arbekacin.Approved
ArotinololArotinolol may increase the bradycardic activities of Digitoxin.Approved
Arsenic trioxideDigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ASA404Digitoxin may decrease the cardiotoxic activities of ASA404.Investigational
AsparaginaseDigitoxin may decrease the cardiotoxic activities of Asparaginase.Approved
AstemizoleThe serum concentration of Digitoxin can be increased when it is combined with Astemizole.Approved, Withdrawn
AT-101Digitoxin may decrease the cardiotoxic activities of AT-101.Investigational
AtazanavirThe metabolism of Digitoxin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Digitoxin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Digitoxin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Digitoxin can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved
AxitinibDigitoxin may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineDigitoxin may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineDigitoxin may decrease the cardiotoxic activities of Azathioprine.Approved
AZD2171Digitoxin may decrease the cardiotoxic activities of AZD2171.Investigational
Azd4547Digitoxin may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidDigitoxin may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzelastineThe serum concentration of Digitoxin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Digitoxin can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatDigitoxin may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Digitoxin.Experimental
BelinostatDigitoxin may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanDigitoxin may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineDigitoxin may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digitoxin.Approved
BenzocaineThe serum concentration of Digitoxin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Digitoxin can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinDigitoxin may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Digitoxin.Approved
Betulinic AcidDigitoxin may decrease the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabDigitoxin may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Digitoxin.Approved
BexaroteneDigitoxin may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Digitoxin may decrease the cardiotoxic activities of Bgj398.Investigational
BicalutamideDigitoxin may decrease the cardiotoxic activities of Bicalutamide.Approved
BiperidenThe serum concentration of Digitoxin can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the bradycardic activities of Digitoxin.Approved
BizelesinDigitoxin may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinDigitoxin may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabDigitoxin may decrease the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Digitoxin may decrease the cardiotoxic activities of Bmn 673.Investigational
BoceprevirThe metabolism of Digitoxin can be decreased when combined with Boceprevir.Approved
BopindololBopindolol may increase the bradycardic activities of Digitoxin.Approved
BortezomibDigitoxin may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosentanThe serum concentration of Digitoxin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibDigitoxin may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinDigitoxin may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Digitoxin can be increased when it is combined with Bromocriptine.Approved, Investigational
BroxuridineDigitoxin may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Digitoxin may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Digitoxin may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Digitoxin.Investigational
BufuralolBufuralol may increase the bradycardic activities of Digitoxin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.Approved
BupranololBupranolol may increase the bradycardic activities of Digitoxin.Approved
BuprenorphineThe serum concentration of Digitoxin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Digitoxin can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanDigitoxin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineDigitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelDigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineDigitoxin may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibDigitoxin may decrease the cardiotoxic activities of Cabozantinib.Approved
CaffeineThe serum concentration of Digitoxin can be increased when it is combined with Caffeine.Approved
CaiDigitoxin may decrease the cardiotoxic activities of Cai.Investigational
CalcidiolCalcidiol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
CalcipotriolDigitoxin may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Digitoxin.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium carbonateCalcium carbonate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium citrateCalcium citrate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Digitoxin.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Digitoxin.Approved, Vet Approved
CamptothecinDigitoxin may decrease the cardiotoxic activities of Camptothecin.Experimental
CanagliflozinThe serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Digitoxin can be increased when it is combined with Candesartan.Approved
CapecitabineDigitoxin may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Digitoxin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Digitoxin can be increased when combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Digitoxin can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Digitoxin can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinDigitoxin may decrease the cardiotoxic activities of Carboplatin.Approved
CarfilzomibDigitoxin may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurDigitoxin may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineDigitoxin may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Digitoxin.Approved
CarvedilolThe serum concentration of Digitoxin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Digitoxin can be increased when it is combined with Caspofungin.Approved
CatumaxomabDigitoxin may decrease the cardiotoxic activities of Catumaxomab.Investigational
CB1954Digitoxin may decrease the cardiotoxic activities of CB1954.Experimental
CediranibDigitoxin may decrease the cardiotoxic activities of Cediranib.Investigational
CelecoxibDigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
CeritinibThe serum concentration of Digitoxin can be increased when it is combined with Ceritinib.Approved
CetuximabDigitoxin may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilDigitoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Digitoxin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.Approved, Vet Approved
ChlorotrianiseneDigitoxin may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Digitoxin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Digitoxin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Digitoxin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
CholesterolThe serum concentration of Digitoxin can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Digitoxin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Digitoxin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Digitoxin can be decreased when it is combined with Cimetidine.Approved
CinoxacinDigitoxin may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinDigitoxin may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved
CisplatinDigitoxin may decrease the cardiotoxic activities of Cisplatin.Approved
CitalopramThe serum concentration of Digitoxin can be increased when it is combined with Citalopram.Approved
CladribineDigitoxin may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Digitoxin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Digitoxin can be decreased when combined with Clemastine.Approved
ClofarabineDigitoxin may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Digitoxin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Digitoxin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved
clorarabineDigitoxin may decrease the cardiotoxic activities of clorarabine.Investigational
ClotrimazoleThe metabolism of Digitoxin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Digitoxin can be decreased when combined with Cobicistat.Approved
ColchicineDigitoxin may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Digitoxin can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Digitoxin can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinDigitoxin may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibDigitoxin may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibDigitoxin may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminDigitoxin may decrease the cardiotoxic activities of Curcumin.Investigational
CyclophosphamideDigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Digitoxin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateDigitoxin may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineDigitoxin may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.Approved
DacarbazineDigitoxin may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Digitoxin can be increased when it is combined with Daclatasvir.Approved
DactinomycinDigitoxin may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabDigitoxin may decrease the cardiotoxic activities of Daratumumab.Approved
DarunavirThe metabolism of Digitoxin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Digitoxin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDigitoxin may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Digitoxin.Approved
DecitabineDigitoxin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Digitoxin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Digitoxin can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxDigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinDigitoxin may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DesipramineThe serum concentration of Digitoxin can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Digitoxin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneDigitoxin may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneDigitoxin may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Digitoxin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Digitoxin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienogestDigitoxin may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolDigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DigoxinThe serum concentration of Digitoxin can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinThe serum concentration of Digitoxin can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Digitoxin.Approved
DiindolylmethaneDigitoxin may decrease the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemThe metabolism of Digitoxin can be decreased when combined with Diltiazem.Approved
DinutuximabDigitoxin may decrease the cardiotoxic activities of Dinutuximab.Approved
DipyridamoleThe serum concentration of Digitoxin can be increased when it is combined with Dipyridamole.Approved
DocetaxelDigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Digitoxin.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Digitoxin.Approved
DoxazosinThe serum concentration of Digitoxin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Digitoxin can be increased when it is combined with Doxepin.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Digitoxin.Approved
DoxifluridineDigitoxin may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinDigitoxin may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Digitoxin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Digitoxin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Digitoxin can be decreased when combined with Dronedarone.Approved
EcabetDigitoxin may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved
efaproxiralDigitoxin may decrease the cardiotoxic activities of efaproxiral.Investigational
EfavirenzThe serum concentration of Digitoxin can be decreased when it is combined with Efavirenz.Approved, Investigational
EflornithineDigitoxin may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Digitoxin may decrease the cardiotoxic activities of EG009.Investigational
ElbasvirThe serum concentration of Digitoxin can be increased when it is combined with Elbasvir.Approved
ElsamitrucinDigitoxin may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EnalaprilThe serum concentration of Digitoxin can be increased when it is combined with Enalapril.Approved, Vet Approved
EndostatinDigitoxin may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinDigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinDigitoxin may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatDigitoxin may decrease the cardiotoxic activities of Entinostat.Investigational
EnzalutamideThe serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.Approved
EpirubicinDigitoxin may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone.Approved
EpofolateDigitoxin may decrease the cardiotoxic activities of Epofolate.Investigational
Epothilone BDigitoxin may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Digitoxin.Approved, Nutraceutical
ErgonovineThe serum concentration of Digitoxin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Digitoxin can be increased when it is combined with Ergotamine.Approved
EribulinDigitoxin may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibDigitoxin may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Digitoxin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Digitoxin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the bradycardic activities of Digitoxin.Approved
EstramustineDigitoxin may decrease the cardiotoxic activities of Estramustine.Approved
EstriolThe serum concentration of Digitoxin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Digitoxin can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.Approved
EtanidazoleDigitoxin may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilDigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateDigitoxin may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideDigitoxin may decrease the cardiotoxic activities of Etoposide.Approved
EtravirineThe serum concentration of Digitoxin can be decreased when it is combined with Etravirine.Approved
EverolimusDigitoxin may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanDigitoxin may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneDigitoxin may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindDigitoxin may decrease the cardiotoxic activities of exisulind.Investigational
FelodipineThe serum concentration of Digitoxin can be increased when it is combined with Felodipine.Approved, Investigational
FenretinideDigitoxin may decrease the cardiotoxic activities of Fenretinide.Investigational
FentanylThe serum concentration of Digitoxin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Digitoxin can be increased when it is combined with Fexofenadine.Approved
FiacitabineDigitoxin may decrease the cardiotoxic activities of Fiacitabine.Investigational
FidaxomicinThe serum concentration of Digitoxin can be increased when it is combined with Fidaxomicin.Approved
FlavopiridolDigitoxin may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FleroxacinDigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineDigitoxin may decrease the cardiotoxic activities of Floxuridine.Approved
FluconazoleThe metabolism of Digitoxin can be decreased when combined with Fluconazole.Approved
FludarabineDigitoxin may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineDigitoxin may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilDigitoxin may decrease the cardiotoxic activities of Fluorouracil.Approved
FluoxetineThe serum concentration of Digitoxin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Digitoxin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Digitoxin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Digitoxin can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideDigitoxin may decrease the cardiotoxic activities of Flutamide.Approved
FluvoxamineThe metabolism of Digitoxin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneDigitoxin may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinDigitoxin may decrease the cardiotoxic activities of Formycin.Experimental
FosamprenavirThe metabolism of Digitoxin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Digitoxin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Digitoxin can be increased when combined with Fosphenytoin.Approved
FotemustineDigitoxin may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Digitoxin can be decreased when it is combined with Framycetin.Approved
FulvestrantDigitoxin may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinDigitoxin may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Digitoxin can be increased when it is combined with Fusidic Acid.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Digitoxin.Approved
Gallium nitrateDigitoxin may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinDigitoxin may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinDigitoxin may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibDigitoxin may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinDigitoxin may decrease the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineDigitoxin may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinDigitoxin may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinDigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinThe serum concentration of Digitoxin can be decreased when it is combined with Geneticin.Experimental
GenisteinDigitoxin may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Digitoxin can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Digitoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CDigitoxin may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Digitoxin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Digitoxin can be increased when it is combined with Glycerol.Experimental
GoserelinDigitoxin may decrease the cardiotoxic activities of Goserelin.Approved
Gramicidin DThe serum concentration of Digitoxin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinDigitoxin may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GusperimusDigitoxin may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinDigitoxin may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneDigitoxin may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Digitoxin can be increased when it is combined with Haloperidol.Approved
HexestrolDigitoxin may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Digitoxin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin.Approved
HydroxychloroquineThe serum concentration of Digitoxin can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateDigitoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaDigitoxin may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Digitoxin can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibDigitoxin may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinDigitoxin may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Digitoxin can be increased when it is combined with Idelalisib.Approved
IfosfamideDigitoxin may decrease the cardiotoxic activities of Ifosfamide.Approved
Il 4Digitoxin may decrease the cardiotoxic activities of Il 4.Investigational
ImatinibDigitoxin may decrease the cardiotoxic activities of Imatinib.Approved
ImipramineThe serum concentration of Digitoxin can be increased when it is combined with Imipramine.Approved
ImiquimodDigitoxin may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.Approved
IndenololIndenolol may increase the bradycardic activities of Digitoxin.Withdrawn
IndinavirThe metabolism of Digitoxin can be decreased when combined with Indinavir.Approved
IndirubinDigitoxin may decrease the cardiotoxic activities of Indirubin.Investigational
IndomethacinThe serum concentration of Digitoxin can be increased when it is combined with Indomethacin.Approved, Investigational
INNO-206The serum concentration of Digitoxin can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aDigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bDigitoxin may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneDigitoxin may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabDigitoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanDigitoxin may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenDigitoxin may decrease the cardiotoxic activities of Irofulven.Investigational
IsavuconazoniumThe metabolism of Digitoxin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Digitoxin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Digitoxin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Digitoxin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Digitoxin can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxabepiloneDigitoxin may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibDigitoxin may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Digitoxin can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Digitoxin can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Digitoxin can be decreased when it is combined with Kaolin.Approved
KetamineThe serum concentration of Digitoxin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Digitoxin can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Digitoxin can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Digitoxin may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineDigitoxin may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Digitoxin.Approved
LanreotideDigitoxin may decrease the cardiotoxic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Digitoxin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibDigitoxin may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LeflunomideDigitoxin may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideDigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
LenvatinibDigitoxin may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleDigitoxin may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideDigitoxin may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Digitoxin.Approved
LevofloxacinDigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Digitoxin can be decreased when it is combined with Levothyroxine.Approved
LiarozoleDigitoxin may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Digitoxin.Approved
LidocaineThe serum concentration of Digitoxin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Digitoxin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Digitoxin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Digitoxin can be increased when it is combined with Lisinopril.Approved, Investigational
LomefloxacinDigitoxin may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomitapideThe serum concentration of Digitoxin can be increased when it is combined with Lomitapide.Approved
LomustineDigitoxin may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineDigitoxin may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Digitoxin can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Digitoxin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Digitoxin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Digitoxin can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Digitoxin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Digitoxin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Digitoxin can be decreased when it is combined with Lumacaftor.Approved
Ly2801653Digitoxin may decrease the cardiotoxic activities of Ly2801653.Investigational
LycopeneDigitoxin may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideDigitoxin may decrease the cardiotoxic activities of Mafosfamide.Investigational
MaprotilineThe serum concentration of Digitoxin can be increased when it is combined with Maprotiline.Approved
MasitinibDigitoxin may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolDigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolDigitoxin may decrease the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Digitoxin may decrease the cardiotoxic activities of MDX-1106.Investigational
MebendazoleDigitoxin may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineDigitoxin may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneDigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateDigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Digitoxin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateDigitoxin may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanDigitoxin may decrease the cardiotoxic activities of Melphalan.Approved
MeprobamateThe serum concentration of Digitoxin can be increased when it is combined with Meprobamate.Approved, Illicit
MequinolDigitoxin may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineDigitoxin may decrease the cardiotoxic activities of Mercaptopurine.Approved
MesalazineThe serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.Approved
MethadoneThe serum concentration of Digitoxin can be increased when it is combined with Methadone.Approved
MethimazoleThe serum concentration of Digitoxin can be increased when it is combined with Methimazole.Approved
MethotrexateDigitoxin may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.Approved
Methyl aminolevulinateDigitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneDigitoxin may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneDigitoxin may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololMetipranolol may increase the bradycardic activities of Digitoxin.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Digitoxin.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Digitoxin.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.Approved
MetoprololThe serum concentration of Digitoxin can be increased when it is combined with Metoprolol.Approved, Investigational
MetrizamideThe serum concentration of Digitoxin can be decreased when it is combined with Metrizamide.Approved
MGI-114Digitoxin may decrease the cardiotoxic activities of MGI-114.Investigational
MibefradilThe serum concentration of Digitoxin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Digitoxin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Digitoxin can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineDigitoxin may increase the bradycardic activities of Midodrine.Approved
MidostaurinDigitoxin may decrease the cardiotoxic activities of Midostaurin.Investigational
MifepristoneThe serum concentration of Digitoxin can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineDigitoxin may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleDigitoxin may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneDigitoxin may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolDigitoxin may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinDigitoxin may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneThe serum concentration of Digitoxin can be decreased when it is combined with Mitotane.Approved
MitoxantroneDigitoxin may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Digitoxin.Approved
MizoribineDigitoxin may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Digitoxin may decrease the cardiotoxic activities of MLN576.Investigational
ModafinilThe serum concentration of Digitoxin can be decreased when it is combined with Modafinil.Approved, Investigational
MolgramostimDigitoxin may decrease the cardiotoxic activities of Molgramostim.Investigational
MorphineThe serum concentration of Digitoxin can be increased when it is combined with Morphine.Approved, Investigational
motexafin gadoliniumDigitoxin may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinDigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadololNadolol may increase the bradycardic activities of Digitoxin.Approved
NafcillinThe serum concentration of Digitoxin can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidDigitoxin may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Digitoxin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NamitecanDigitoxin may decrease the cardiotoxic activities of Namitecan.Investigational
NaringeninThe serum concentration of Digitoxin can be increased when it is combined with Naringenin.Experimental
NavitoclaxDigitoxin may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Digitoxin can be decreased when it is combined with Neamine.Experimental
NecitumumabDigitoxin may decrease the cardiotoxic activities of Necitumumab.Approved
NefazodoneThe metabolism of Digitoxin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineDigitoxin may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Digitoxin can be decreased when combined with Nelfinavir.Approved
NeomycinThe serum concentration of Digitoxin can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Digitoxin.Investigational
NeostigmineThe serum concentration of Digitoxin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetilmicinThe serum concentration of Digitoxin can be decreased when it is combined with Netilmicin.Approved
NetupitantThe serum concentration of Digitoxin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Digitoxin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Digitoxin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Digitoxin can be decreased when it is combined with Nifedipine.Approved
NiguldipineDigitoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibDigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideDigitoxin may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineDigitoxin may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibDigitoxin may decrease the cardiotoxic activities of Nintedanib.Approved
NisoldipineThe serum concentration of Digitoxin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Digitoxin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Digitoxin can be increased when it is combined with Nitrendipine.Approved
NivolumabDigitoxin may decrease the cardiotoxic activities of Nivolumab.Approved
Nk012Digitoxin may decrease the cardiotoxic activities of Nk012.Investigational
nocodazoleDigitoxin may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedDigitoxin may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorethisteroneThe serum concentration of Digitoxin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinDigitoxin may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabDigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideDigitoxin may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabDigitoxin may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinDigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
OlaparibDigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Digitoxin can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateDigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OmeprazoleThe serum concentration of Digitoxin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinDigitoxin may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Digitoxin can be increased when it is combined with Osimertinib.Approved
OxaliplatinDigitoxin may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxprenololOxprenolol may increase the bradycardic activities of Digitoxin.Approved
P-NitrophenolThe serum concentration of Digitoxin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelDigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Digitoxin can be increased when it is combined with Palbociclib.Approved
PalifosfamideDigitoxin may decrease the cardiotoxic activities of Palifosfamide.Investigational
Palmitic AcidThe serum concentration of Digitoxin can be increased when it is combined with Palmitic Acid.Experimental
PamidronateDigitoxin may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Digitoxin.Approved
PanitumumabDigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatDigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Digitoxin can be increased when it is combined with Pantoprazole.Approved
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
ParomomycinThe serum concentration of Digitoxin can be decreased when it is combined with Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Digitoxin can be increased when it is combined with Paroxetine.Approved, Investigational
PARP inhibitorDigitoxin may decrease the cardiotoxic activities of PARP inhibitor.Investigational
PazopanibDigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinDigitoxin may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinDigitoxin may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseDigitoxin may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabDigitoxin may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedDigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
PenclomedineDigitoxin may decrease the cardiotoxic activities of Penclomedine.Investigational
PentobarbitalThe metabolism of Digitoxin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinDigitoxin may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Digitoxin can be increased when it is combined with Perindopril.Approved
PertuzumabDigitoxin may decrease the cardiotoxic activities of Pertuzumab.Approved
PhenobarbitalThe metabolism of Digitoxin can be increased when combined with Phenobarbital.Approved
Phenylacetic acidDigitoxin may decrease the cardiotoxic activities of Phenylacetic acid.Approved
PhenytoinThe metabolism of Digitoxin can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Digitoxin can be increased when it is combined with Pimozide.Approved
PindololPindolol may increase the bradycardic activities of Digitoxin.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
PipobromanDigitoxin may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinDigitoxin may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.Experimental
PirfenidoneDigitoxin may decrease the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleDigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneDigitoxin may decrease the cardiotoxic activities of Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Digitoxin can be decreased when it is combined with Platelet Activating Factor.Experimental
PlevitrexedDigitoxin may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinDigitoxin may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxDigitoxin may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinDigitoxin may decrease the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidDigitoxin may decrease the cardiotoxic activities of polyacrylic acid.Investigational
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Digitoxin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digitoxin.Approved
PomalidomideDigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibDigitoxin may decrease the cardiotoxic activities of Ponatinib.Approved
PorfimerDigitoxin may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinDigitoxin may decrease the cardiotoxic activities of porfiromycin.Investigational
PosaconazoleThe metabolism of Digitoxin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the bradycardic activities of Digitoxin.Approved
PralatrexateDigitoxin may decrease the cardiotoxic activities of Pralatrexate.Approved
PravastatinThe serum concentration of Digitoxin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Digitoxin can be increased when it is combined with Prazosin.Approved
PrednimustineDigitoxin may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneDigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneDigitoxin may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Digitoxin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Digitoxin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Digitoxin can be increased when it is combined with Probenecid.Approved
ProcarbazineDigitoxin may decrease the cardiotoxic activities of Procarbazine.Approved
ProgesteroneThe serum concentration of Digitoxin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Digitoxin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Digitoxin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Digitoxin can be increased when it is combined with Propranolol.Approved, Investigational
PropylthiouracilThe serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil.Approved
ProtriptylineThe serum concentration of Digitoxin can be increased when it is combined with Protriptyline.Approved
Purine RibosideDigitoxin may decrease the cardiotoxic activities of Purine Riboside.Experimental
PuromycinDigitoxin may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Digitoxin.Approved, Vet Approved
PyrazoloacridineDigitoxin may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
Qlt091001Digitoxin may decrease the cardiotoxic activities of Qlt091001.Investigational
QuercetinThe serum concentration of Digitoxin can be increased when it is combined with Quercetin.Experimental
QuinacrineDigitoxin may decrease the cardiotoxic activities of Quinacrine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin.Approved
QuinidineThe serum concentration of Digitoxin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Digitoxin can be increased when it is combined with Quinine.Approved
Radium Ra 223 DichlorideDigitoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedDigitoxin may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabDigitoxin may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabDigitoxin may decrease the cardiotoxic activities of Ranibizumab.Approved
RanitidineThe serum concentration of Digitoxin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Digitoxin can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseDigitoxin may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Digitoxin.Withdrawn
ReboxetineThe serum concentration of Digitoxin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibDigitoxin may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin.Approved
ResveratrolDigitoxin may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GDigitoxin may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin.Approved
RifabutinThe metabolism of Digitoxin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Digitoxin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Digitoxin can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Digitoxin can be increased when it is combined with Rilpivirine.Approved
RitonavirThe metabolism of Digitoxin can be decreased when combined with Ritonavir.Approved, Investigational
RituximabDigitoxin may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Digitoxin.Approved
RolapitantThe serum concentration of Digitoxin can be increased when it is combined with Rolapitant.Approved
RomidepsinDigitoxin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimDigitoxin may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexDigitoxin may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanDigitoxin may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibDigitoxin may decrease the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibDigitoxin may decrease the cardiotoxic activities of Ruxolitinib.Approved
SalirasibDigitoxin may decrease the cardiotoxic activities of Salirasib.Investigational
SaquinavirThe metabolism of Digitoxin can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibDigitoxin may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinDigitoxin may decrease the cardiotoxic activities of Satraplatin.Investigational
ScopolamineThe serum concentration of Digitoxin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Digitoxin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeliciclibDigitoxin may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibDigitoxin may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolDigitoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental
SertralineThe serum concentration of Digitoxin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Digitoxin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Digitoxin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Digitoxin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Digitoxin can be increased when it is combined with Simvastatin.Approved
SirolimusDigitoxin may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Digitoxin can be decreased when it is combined with Sisomicin.Investigational
Sodium phenylbutyrateDigitoxin may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved
SolithromycinThe serum concentration of Digitoxin can be increased when it is combined with Solithromycin.Investigational
SonidegibDigitoxin may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanDigitoxin may decrease the cardiotoxic activities of Sonifilan.Investigational
SorafenibDigitoxin may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Digitoxin.Approved
SP1049CThe serum concentration of Digitoxin can be decreased when it is combined with SP1049C.Investigational
SparfloxacinDigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidDigitoxin may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinDigitoxin may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Digitoxin can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SpiramycinThe serum concentration of Digitoxin can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe serum concentration of Digitoxin can be increased when it is combined with Spironolactone.Approved
squalamineDigitoxin may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Digitoxin may decrease the cardiotoxic activities of SRT501.Investigational
St. John's WortThe serum concentration of Digitoxin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Digitoxin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Digitoxin can be increased when it is combined with Stiripentol.Approved
StreptomycinThe serum concentration of Digitoxin can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinDigitoxin may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Digitoxin.Approved
SulfasalazineThe serum concentration of Digitoxin can be decreased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Digitoxin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Digitoxin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneDigitoxin may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacDigitoxin may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.Approved
SumatriptanThe serum concentration of Digitoxin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibDigitoxin may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminDigitoxin may decrease the cardiotoxic activities of Suramin.Approved
SwainsonineDigitoxin may decrease the cardiotoxic activities of Swainsonine.Experimental
TacrineThe serum concentration of Digitoxin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Digitoxin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TalaporfinDigitoxin may decrease the cardiotoxic activities of Talaporfin.Investigational
TamoxifenDigitoxin may decrease the cardiotoxic activities of Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Digitoxin can be increased when it is combined with Taurocholic Acid.Experimental
TegafurDigitoxin may decrease the cardiotoxic activities of Tegafur.Approved
TelaprevirThe metabolism of Digitoxin can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Digitoxin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Digitoxin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinDigitoxin may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinDigitoxin may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideDigitoxin may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusDigitoxin may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideDigitoxin may decrease the cardiotoxic activities of Teniposide.Approved
TerazosinThe serum concentration of Digitoxin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Digitoxin can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Digitoxin can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneDigitoxin may decrease the cardiotoxic activities of Testolactone.Approved
TestosteroneThe serum concentration of Digitoxin can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateDigitoxin may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineDigitoxin may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideDigitoxin may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaDigitoxin may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinDigitoxin may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneDigitoxin may decrease the cardiotoxic activities of Tibolone.Approved
TicagrelorThe serum concentration of Digitoxin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Digitoxin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the bradycardic activities of Digitoxin.Approved
TioguanineDigitoxin may decrease the cardiotoxic activities of Tioguanine.Approved
TipifarnibDigitoxin may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineDigitoxin may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibDigitoxin may decrease the cardiotoxic activities of Tivozanib.Investigational
Tnp 470Digitoxin may decrease the cardiotoxic activities of Tnp 470.Investigational
TobramycinThe serum concentration of Digitoxin can be decreased when it is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Digitoxin can be increased when it is combined with Tolvaptan.Approved
TopotecanDigitoxin may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.Approved
ToremifeneDigitoxin may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabDigitoxin may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinDigitoxin may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibDigitoxin may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabDigitoxin may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineDigitoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Digitoxin can be decreased when it is combined with Trazodone.Approved, Investigational
TreosulfanDigitoxin may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarDigitoxin may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinDigitoxin may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Digitoxin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Digitoxin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineDigitoxin may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneDigitoxin may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Digitoxin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateDigitoxin may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Digitoxin can be increased when it is combined with Trimipramine.Approved
TriptorelinDigitoxin may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideDigitoxin may decrease the cardiotoxic activities of Trofosfamide.Investigational
TroleandomycinThe serum concentration of Digitoxin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinDigitoxin may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineDigitoxin may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBDigitoxin may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinDigitoxin may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Digitoxin.Approved
TylosinThe serum concentration of Digitoxin can be increased when it is combined with Tylosin.Vet Approved
UbenimexDigitoxin may decrease the cardiotoxic activities of Ubenimex.Experimental
Uracil mustardDigitoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanDigitoxin may decrease the cardiotoxic activities of Vadimezan.Investigational
Val 083Digitoxin may decrease the cardiotoxic activities of Val 083.Investigational
ValrubicinDigitoxin may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibDigitoxin may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideDigitoxin may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Digitoxin.Approved
VeliparibDigitoxin may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibDigitoxin may decrease the cardiotoxic activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Digitoxin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Digitoxin can be decreased when combined with Verapamil.Approved
VerteporfinDigitoxin may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneDigitoxin may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineDigitoxin may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineDigitoxin may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineDigitoxin may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineDigitoxin may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineDigitoxin may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideDigitoxin may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibDigitoxin may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin ADigitoxin may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Digitoxin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatDigitoxin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
ZimelidineThe serum concentration of Digitoxin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Digitoxin can be decreased when combined with Ziprasidone.Approved
ZorubicinDigitoxin may decrease the cardiotoxic activities of Zorubicin.Experimental
Food Interactions
  • Avoid avocado.
  • Avoid bran and high fiber foods within 2 hours of taking this medication.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid salt substitutes containing potassium.
  • Limit garlic, ginger, gingko, and horse chestnut.
References
Synthesis ReferenceNot Available
General References
  1. Belz GG, Breithaupt-Grogler K, Osowski U: Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. [PubMed:11525233 ]
  2. Kurowski V, Iven H, Djonlagic H: Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med. 1992;18(7):439-42. [PubMed:1469187 ]
  3. Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. 2001 Jun;12(5):475-83. [PubMed:11395576 ]
  4. Hippius M, Humaid B, Sicker T, Hoffmann A, Gottler M, Hasford J: Adverse drug reaction monitoring--digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther. 2001 Aug;39(8):336-43. [PubMed:11515708 ]
External Links
ATC CodesC01AA04
AHFS Codes
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9718
Blood Brain Barrier-0.557
Caco-2 permeable-0.8386
P-glycoprotein substrateSubstrate0.8528
P-glycoprotein inhibitor IInhibitor0.5557
P-glycoprotein inhibitor IINon-inhibitor0.6021
Renal organic cation transporterNon-inhibitor0.8473
CYP450 2C9 substrateNon-substrate0.8687
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.8902
CYP450 2C9 inhibitorNon-inhibitor0.9082
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9258
CYP450 3A4 inhibitorNon-inhibitor0.901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9381
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.9637
BiodegradationNot ready biodegradable0.9671
Rat acute toxicity4.4764 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Inhibitor0.7759
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral.1 mg
Prices
Unit descriptionCostUnit
Digitoxin powder486.85USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point255.5 °CPhysProp
water solubility3.9 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.85SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0289 mg/mLALOGPS
logP2.33ALOGPS
logP3.6ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)0.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area182.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity191.72 m3·mol-1ChemAxon
Polarizability83.58 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (12.6 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-052g-9620000000-5ddc0df4702d2f0b8581View in MoNA
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • Oxane
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248 ]
  2. Marcus FI, Ryan JN, Stafford MG: The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay. J Lab Clin Med. 1975 Apr;85(4):610-20. [PubMed:123547 ]
  3. Prignitz R, Frohlich D, Hoffmeister G: [Influence of roentgen rays on electrolyte changes and metabolism of the myocardium. VII. Radiation-induced inhibition of the sodium- and potassium--activated microscomal-trasport ATPase]. Strahlentherapie. 1976 Apr;151(4):356-65. [PubMed:131389 ]
  4. Bluschke V, Bonn R, Greeff K: Increase in the (Na+ + K+)-ATPase activity in heart muscle after chronic treatment with digitoxin or potassium deficient diet. Eur J Pharmacol. 1976 May;37(1):189-91. [PubMed:132355 ]
  5. Fricke U: [New aspects on the mode of action of cardiac glycosides]. Fortschr Med. 1976 Nov 11;94(32):1037-45. [PubMed:136410 ]
  6. Hauck C, Potter T, Bartz M, Wittwer T, Wahlers T, Mehlhorn U, Scheiner-Bobis G, McDonough AA, Bloch W, Schwinger RH, Muller-Ehmsen J: Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase alpha1beta1, alpha2beta1 and alpha3beta1. Eur J Pharmacol. 2009 Nov 10;622(1-3):7-14. doi: 10.1016/j.ejphar.2009.08.039. Epub 2009 Sep 12. [PubMed:19751721 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Wang SW, Lin H, Hwang JJ, Wang PS: Inhibition of testosterone secretion by digitoxin in rat testicular interstitial cells. J Cell Biochem. 1999 Jul 1;74(1):74-80. [PubMed:10381263 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Hage DS, Sengupta A: Characterisation of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography. J Chromatogr B Biomed Sci Appl. 1999 Mar 5;724(1):91-100. [PubMed:10202961 ]
  2. Dasgupta A, Vega AE, Wells A, Datta P: Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques. Ther Drug Monit. 1999 Dec;21(6):625-30. [PubMed:10604823 ]
  3. Datta P, Dasgupta A: Interactions between drugs and Asian medicine: displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicines Chan Su and Lu-Shen-Wan. Ther Drug Monit. 2000 Apr;22(2):155-9. [PubMed:10774625 ]
  4. Dasgupta A, Paul A, Wells A: Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am J Med Sci. 2001 Oct;322(4):204-8. [PubMed:11678517 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF: P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43. [PubMed:11284449 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:03 / Updated on August 17, 2016 12:23